KR920000326A - 사람에 있어서 몰핀 및 동족체의 진통 효과에 대한 내성 발생을 방지하기 위한 gm₁모노시알로강글리오사이드 및 이의 내부 에스테르 유도체의 용도 - Google Patents

사람에 있어서 몰핀 및 동족체의 진통 효과에 대한 내성 발생을 방지하기 위한 gm₁모노시알로강글리오사이드 및 이의 내부 에스테르 유도체의 용도 Download PDF

Info

Publication number
KR920000326A
KR920000326A KR1019910011010A KR910011010A KR920000326A KR 920000326 A KR920000326 A KR 920000326A KR 1019910011010 A KR1019910011010 A KR 1019910011010A KR 910011010 A KR910011010 A KR 910011010A KR 920000326 A KR920000326 A KR 920000326A
Authority
KR
South Korea
Prior art keywords
humans
active ingredient
pharmaceutical composition
morphine
resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019910011010A
Other languages
English (en)
Korean (ko)
Inventor
델라 발레 프란세스코
토파노 지노
Original Assignee
피디아 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피디아 에스.피.에이. filed Critical 피디아 에스.피.에이.
Publication of KR920000326A publication Critical patent/KR920000326A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
KR1019910011010A 1990-06-29 1991-06-29 사람에 있어서 몰핀 및 동족체의 진통 효과에 대한 내성 발생을 방지하기 위한 gm₁모노시알로강글리오사이드 및 이의 내부 에스테르 유도체의 용도 Withdrawn KR920000326A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT02082290A IT1249034B (it) 1990-06-29 1990-06-29 Impiego del monosialoganglioside gm1 e del suo derivato estere interno per impedire l'instaurarsi della tolleranza nell'uomo all'effetto analgesico della morfina e analoghi
IT20822A/90 1990-06-29

Publications (1)

Publication Number Publication Date
KR920000326A true KR920000326A (ko) 1992-01-29

Family

ID=11172568

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910011010A Withdrawn KR920000326A (ko) 1990-06-29 1991-06-29 사람에 있어서 몰핀 및 동족체의 진통 효과에 대한 내성 발생을 방지하기 위한 gm₁모노시알로강글리오사이드 및 이의 내부 에스테르 유도체의 용도

Country Status (9)

Country Link
US (1) US5183807A (enExample)
EP (1) EP0463614A3 (enExample)
JP (1) JPH04230327A (enExample)
KR (1) KR920000326A (enExample)
AU (1) AU7948491A (enExample)
CA (1) CA2045982A1 (enExample)
HU (1) HUT58206A (enExample)
IT (1) IT1249034B (enExample)
PT (1) PT98160A (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251991B (it) * 1991-11-08 1995-05-27 Fidia Spa Impiego di gangliosidi per la preparazione di composizioni farmaceutiche attive nella prevenzione di disfunzioni associate all'abuso di cocaina e psicostimolanti ad essa collegati
IT1254280B (it) * 1992-03-13 1995-09-14 Fidia Spa Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
US5834479A (en) * 1993-03-05 1998-11-10 Mayer; David J. Method and composition for alleviating pain
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US6962930B1 (en) 1997-06-06 2005-11-08 Lohocla Research Corporation Compounds, compositions and method suitable for amelioration of withdrawal syndromes and withdrawal-induced brain damage
MXPA04001831A (es) 2001-08-29 2004-07-08 Neose Technologies Inc Nuevos derivados sinteticos de gangliosidos y composiciones de los mismos.
US20040024005A1 (en) * 2002-01-23 2004-02-05 The Regents Of The University Of California Methods and compositions for reducing the development of drug tolerance and/or physical dependence
JP2006519878A (ja) 2003-03-06 2006-08-31 ネオーズ テクノロジーズ， インコーポレイテッド ガングリオシドの酵素合成のための方法および化合物
US20080241121A1 (en) * 2007-04-02 2008-10-02 Daniela Salvemini Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain
US20100086543A1 (en) * 2007-04-02 2010-04-08 Saint Louis University Compositions and methods for treating conditions associated with ceramide biosynthesis
EP2410846B1 (en) 2009-03-25 2016-09-07 Seneb Biosciences, Inc. Glycolipids as treatment for disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476119A (en) * 1981-08-04 1984-10-09 Fidia S.P.A. Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions
IT1212896B (it) * 1983-11-08 1989-11-30 Della Valle Francesco Metodo di somministrazione per via inalatoria di gangliosidi e derivati, e composizioni farmaceutiche relative
IT1177863B (it) * 1984-07-03 1987-08-26 Fidia Farmaceutici Una miscela gangliosidica come agente terapeutico capare di eliminare il dolore nele neuropatie periferiche
IT1182209B (it) * 1985-02-18 1987-09-30 Fidia Farmaceutici Uso terapeutico del monosialoganglioside gm1 e dei suoi derivati in gravi patologie di infarti cerebrali
IT1212041B (it) * 1987-11-02 1989-11-08 Fidia Farmaceutici Gangliosidi esteri interni come agenti terapeutici capaci di eliminare il dolore nelle neuropatie periferiche
US5066496A (en) * 1988-08-03 1991-11-19 Angio-Medical Corporation Composition and method for treatment of gastric and duodenal ulcers and mucosal erosions

Also Published As

Publication number Publication date
HU912186D0 (en) 1991-12-30
IT9020822A1 (it) 1991-12-29
CA2045982A1 (en) 1991-12-30
IT1249034B (it) 1995-02-11
US5183807A (en) 1993-02-02
JPH04230327A (ja) 1992-08-19
EP0463614A2 (en) 1992-01-02
AU7948491A (en) 1992-01-16
PT98160A (pt) 1992-04-30
HUT58206A (en) 1992-02-28
EP0463614A3 (en) 1992-07-01
IT9020822A0 (enExample) 1990-06-29

Similar Documents

Publication Publication Date Title
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
KR920007629A (ko) SALMe염, 5-MTHF 및 5-FTHF 중에서 선택된 화합물 적어도 1개를 유효성분으로서 함유하여 AIDS환자의 신경학적 질환치료시 활성을 나타내는 약제학적 조성물
KR920000326A (ko) 사람에 있어서 몰핀 및 동족체의 진통 효과에 대한 내성 발생을 방지하기 위한 gm₁모노시알로강글리오사이드 및 이의 내부 에스테르 유도체의 용도
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
KR920002144A (ko) 아연 l-카르노신 염 또는 이의 착화합물을 유효성분으로 함유하는 염증성 장질환 예방 및 치료제
KR880002515A (ko) 흡수 및 작용이 빠른 설린다크 또는 나트륨 설린다크와 염기의 혼합물
KR870002832A (ko) 제약 조성물
KR910019618A (ko) 발기부전증 치료용 제약 조성물
KR970009799A (ko) 물질 남용 금단의 치료 방법
KR920702217A (ko) 말라리아 치료 조성물
KR930702000A (ko) 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
KR920703041A (ko) 통증을 수반하는 염증성 또는 알레르기성 질환치료에 사용되는 성분물과 그 방법
CA2270955A1 (en) Pharmaceutical composition containing morphinan derivative for treating drug dependence
KR900013969A (ko) 지루를 감소시키는 약학 조성물의 제조에 있어서 5'-데옥시-5'-메틸티오아데노신, s-아데노실메티오닌 및 이들의 염의 용도 및 이와 관련된 약학 조성물
KR950016760A (ko) 치질 치료제
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
KR950016734A (ko) 성적 조숙증의 억제방법
KR900014406A (ko) 세펨 화합물 및 이의 제조방법
KR900701259A (ko) 다가 소염제
KR900005974A (ko) 남성의 성기능 장애 치료제
KR920702225A (ko) 약학 조성물
KR970701191A (ko) 복소환 화합물
JPS615017A (ja) 抗潰瘍組成物
Tosti et al. Contact dermatitis due to chlorpheniramine maleate in eyedrops.

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19910629

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid